4D Molecular Therapeutics (FDMT) Competitors $2.99 -0.24 (-7.43%) Closing price 04:00 PM EasternExtended Trading$2.93 -0.06 (-2.01%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT vs. CRON, PRTA, AVBP, ORGO, CVAC, GHRS, NUVB, CRMD, IMNM, and ABUSShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Cronos Group (CRON), Prothena (PRTA), ArriVent BioPharma (AVBP), Organogenesis (ORGO), CureVac (CVAC), GH Research (GHRS), Nuvation Bio (NUVB), CorMedix (CRMD), Immunome (IMNM), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. Cronos Group Prothena ArriVent BioPharma Organogenesis CureVac GH Research Nuvation Bio CorMedix Immunome Arbutus Biopharma Cronos Group (NASDAQ:CRON) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership. Do insiders & institutionals believe in CRON or FDMT? 8.7% of Cronos Group shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 6.9% of Cronos Group shares are held by insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, CRON or FDMT? Cronos Group has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500. Is CRON or FDMT more profitable? 4D Molecular Therapeutics has a net margin of 0.00% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -2.56% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cronos Group-42.65% -2.56% -2.47% 4D Molecular Therapeutics N/A -28.00%-26.16% Do analysts rate CRON or FDMT? Cronos Group presently has a consensus price target of $3.00, suggesting a potential upside of 64.38%. 4D Molecular Therapeutics has a consensus price target of $26.71, suggesting a potential upside of 788.40%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.004D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 Does the MarketBeat Community prefer CRON or FDMT? Cronos Group received 408 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. However, 66.67% of users gave 4D Molecular Therapeutics an outperform vote while only 61.13% of users gave Cronos Group an outperform vote. CompanyUnderperformOutperformCronos GroupOutperform Votes46461.13% Underperform Votes29538.87% 4D Molecular TherapeuticsOutperform Votes5666.67% Underperform Votes2833.33% Does the media favor CRON or FDMT? In the previous week, Cronos Group had 3 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 5 mentions for Cronos Group and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat Cronos Group's score of 0.41 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral 4D Molecular Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, CRON or FDMT? Cronos Group has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCronos Group$117.62M5.94-$73.96M$0.1018.254D Molecular Therapeutics$37K3,762.98-$100.84M-$2.98-1.01 Summary4D Molecular Therapeutics beats Cronos Group on 11 of the 18 factors compared between the two stocks. Remove Ads Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$138.81M$2.96B$5.59B$7.87BDividend YieldN/A1.55%5.37%4.05%P/E Ratio-1.0530.5223.5918.70Price / Sales3,762.98401.78371.0588.62Price / CashN/A168.6838.1734.64Price / Book0.423.706.674.11Net Income-$100.84M-$71.95M$3.20B$246.93M7 Day Performance-18.51%-10.09%-5.58%-3.38%1 Month Performance-33.62%-17.47%-0.75%-6.41%1 Year Performance-89.98%-31.13%7.88%-1.66% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.8514 of 5 stars$2.99-7.4%$26.71+793.5%-89.9%$138.44M$37,000.00-1.05120CRONCronos Group1.7544 of 5 stars$1.88+5.0%$3.00+59.6%-30.7%$719.16M$117.62M-14.46450PRTAProthena3.2799 of 5 stars$13.34+2.9%$55.00+312.3%-50.0%$718.05M$135.16M-5.80130News CoveragePositive NewsAVBPArriVent BioPharma1.4285 of 5 stars$20.21+3.5%$39.00+93.0%+3.5%$687.46MN/A-7.8640Positive NewsORGOOrganogenesis4.0721 of 5 stars$5.42+11.1%$5.50+1.5%+52.1%$687.41M$482.04M-90.33950CVACCureVac3.8184 of 5 stars$3.00+3.8%$10.00+233.3%-8.6%$671.64M$543.28M5.45880GHRSGH Research2.476 of 5 stars$12.88+3.0%$30.86+139.6%+3.5%$670.12MN/A-16.3010NUVBNuvation Bio1.9646 of 5 stars$1.96+3.4%$8.33+326.3%-51.2%$662.12M$7.87M-0.9060CRMDCorMedix2.6065 of 5 stars$10.77-1.3%$16.00+48.6%+45.3%$653.49M$12.26M-13.3030Earnings ReportAnalyst UpgradeIMNMImmunome2.1151 of 5 stars$8.15-0.4%$25.50+212.9%-72.7%$650.18M$10.13M-1.0040ABUSArbutus Biopharma1.5505 of 5 stars$3.39+3.4%$5.50+62.2%+35.3%$642.38M$6.74M-7.8890Earnings ReportAnalyst Upgrade Remove Ads Related Companies and Tools Related Companies CRON Alternatives PRTA Alternatives AVBP Alternatives ORGO Alternatives CVAC Alternatives GHRS Alternatives NUVB Alternatives CRMD Alternatives IMNM Alternatives ABUS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FDMT) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FDMT Stock Free FDMT Stock Alerts